FGF21 and obesity due to melanocortin 4 receptor deficiency: In the diabetic KKAy mouse model, liraglutide treatment was shown to suppress both obesity and hyperglycemia, associated with increased hepatic FGF21 production (Nonogaki et al., 2014).